Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice
Immune responses against polyethylene glycol (PEG) can lead to the rapid clearance of PEGylated drugs and are associated with increased risk of serious adverse events such as infusion reactions and anaphylaxis. Although select PEGylated therapeutics can induce anti-PEG antibodies (APA), there is currently no readily deployable strategy to mitigate their negative effects.
Given the large number of PEGylated therapeutics that are either FDA-approved or in clinical development, methods that suppress APA induction to ensure the safety and efficacy of PEGylated drugs in patients would be a valuable clinical tool. We previously showed that infusion of high molecular weight (MW) free PEG can safely and effectively restore the circulation of PEG liposomes in animals with high pre-existing titers of APA, without stimulating additional APA production. Here, we explored the effectiveness of prophylaxis with free PEG or tolerogenic PEGylated liposomes in reducing APA induced by subsequently administered PEGylated liposomes.
Surprisingly, we found that a single administration of free PEG alone was capable of markedly reducing the APA response to PEG-liposomes for ~2 months; the effectiveness was comparable to, and frequently exceeded, interventions with different tolerogenic PEG-liposomes. These results support further investigation of free PEG prophylaxis as a strategy to ameliorate the APA response to sensitizing PEGylated therapeutics.
Article Information: Morgan D. McSweeney, Limei Shen, Alexander C. DeWalle, Jordan B. Joiner, Elizabeth C. Ciociola, Dharmendra Raghuwanshi, Matthew S. Macauley, Samuel K. Lai. Journal of Controlled Release, 2020. https://doi.org/10.1016/j.jconrel.2020.10.011